The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. 1982

K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen

Single-dose investigations in healthy subjects have demonstrated substantial impairment of renal and extrarenal clearance of digoxin during coadministration of verapamil. A longitudinal study has been performed to assess the changes in digoxin disposition during long-term verapamil therapy. After one week of verapamil 240 mg/d mean plasma digoxin had risen from 0.21 +/- 0.01 ng/ml (SE) to 0.34 +/- 0.01 ng/ml(p less than 0.01), and renal digoxin clearance had fallen from 197.57 +/- 17.37 ml/min to 128.20 +/- 10.33 ml/min (p less than 0.001). These changes gradually subsided, and after six weeks, renal digoxin clearance had normalized and plasma digoxin had declined to 0.27 +/0 0.02 ng/ml (NS). The 24-h urinary recovery of digoxin increased from 46.46 +/- 3.23% before to 69.78 +/- 3.69% (p less than 0.001) after six weeks of verapamil co-administration, and this elevation persisted throughout the study. The verapamil-induced suppression of renal digoxin elimination disappears over a few weeks of drug exposure, whereas the inhibition of the extrarenal clearance of digoxin seems to persist.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
July 1984, Clinical pharmacology and therapeutics,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
October 1984, Clinical pharmacology and therapeutics,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
October 1978, International journal of clinical pharmacology and biopharmacy,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
January 1982, European journal of clinical pharmacology,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
April 1980, British journal of clinical pharmacology,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
January 1989, European journal of clinical pharmacology,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
March 1991, Clinical pharmacology and therapeutics,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
December 1980, The Journal of pharmacology and experimental therapeutics,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
January 1983, European journal of clinical pharmacology,
K E Pedersen, and A Dorph-Pedersen, and S Hvidt, and N A Klitgaard, and K K Pedersen
January 1982, Cardiologia (Rome, Italy),
Copied contents to your clipboard!